PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

NASDAQ:PYXS • US7473241013

1.45 USD
0 (0%)
Last: Feb 24, 2026, 10:43 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PYXS. PYXS was compared to 521 industry peers in the Biotechnology industry. Both the profitability and financial health of PYXS have multiple concerns. PYXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • PYXS had negative earnings in the past year.
  • In the past year PYXS has reported a negative cash flow from operations.
  • PYXS had negative earnings in each of the past 5 years.
  • In the past 5 years PYXS always reported negative operating cash flow.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • The Return On Assets of PYXS (-78.14%) is worse than 66.03% of its industry peers.
  • With a Return On Equity value of -109.86%, PYXS perfoms like the industry average, outperforming 42.80% of the companies in the same industry.
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • With an excellent Gross Margin value of 555.71%, PYXS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • PYXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 555.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for PYXS has been increased compared to 1 year ago.
  • The number of shares outstanding for PYXS has been increased compared to 5 years ago.
  • Compared to 1 year ago, PYXS has a worse debt to assets ratio.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -4.52, we must say that PYXS is in the distress zone and has some risk of bankruptcy.
  • PYXS has a Altman-Z score (-4.52) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.00 indicates that PYXS is not too dependend on debt financing.
  • PYXS has a Debt to Equity ratio (0.00) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.52
ROIC/WACCN/A
WACC8.72%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 5.65 indicates that PYXS has no problem at all paying its short term obligations.
  • PYXS has a Current ratio of 5.65. This is comparable to the rest of the industry: PYXS outperforms 59.31% of its industry peers.
  • A Quick Ratio of 5.65 indicates that PYXS has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 5.65, PYXS is in the better half of the industry, outperforming 60.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.65
Quick Ratio 5.65
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • PYXS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -21.36%.
EPS 1Y (TTM)-21.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to decrease by -0.03% on average over the next years.
  • Based on estimates for the next years, PYXS will show a very strong growth in Revenue. The Revenue will grow by 33.91% on average per year.
EPS Next Y-42.67%
EPS Next 2Y-13.63%
EPS Next 3Y-13.57%
EPS Next 5Y-0.03%
Revenue Next Year-79.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y-36.29%
Revenue Next 5Y33.91%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -2 -4

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • PYXS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PYXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • PYXS's earnings are expected to decrease with -13.57% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.63%
EPS Next 3Y-13.57%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PYXIS ONCOLOGY INC

NASDAQ:PYXS (2/24/2026, 10:43:41 AM)

1.45

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-16
Inst Owners37.14%
Inst Owner Change8.87%
Ins Owners5.67%
Ins Owner Change0%
Market Cap90.28M
Revenue(TTM)16.15M
Net Income(TTM)-96.29M
Analysts86.67
Price Target6.55 (351.72%)
Short Float %5.08%
Short Ratio1.74
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.17%
Min EPS beat(2)-16.71%
Max EPS beat(2)16.37%
EPS beat(4)2
Avg EPS beat(4)3.97%
Min EPS beat(4)-16.71%
Max EPS beat(4)25.73%
EPS beat(8)5
Avg EPS beat(8)15.93%
EPS beat(12)7
Avg EPS beat(12)16.36%
EPS beat(16)7
Avg EPS beat(16)-119.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.81%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 32.01
P/FCF N/A
P/OCF N/A
P/B 1.03
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-1.25
EYN/A
EPS(NY)-1.23
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.18
OCFYN/A
SpS0.05
BVpS1.41
TBVpS1.37
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -78.14%
ROE -109.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 555.71%
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.65
Quick Ratio 5.65
Altman-Z -4.52
F-Score2
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-21.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-42.67%
EPS Next 2Y-13.63%
EPS Next 3Y-13.57%
EPS Next 5Y-0.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-79.64%
Revenue Next 2Y-41.42%
Revenue Next 3Y-36.29%
Revenue Next 5Y33.91%
EBIT growth 1Y-24.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y16.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.73%
OCF growth 3YN/A
OCF growth 5YN/A

PYXIS ONCOLOGY INC / PYXS FAQ

What is the fundamental rating for PYXS stock?

ChartMill assigns a fundamental rating of 2 / 10 to PYXS.


Can you provide the valuation status for PYXIS ONCOLOGY INC?

ChartMill assigns a valuation rating of 0 / 10 to PYXIS ONCOLOGY INC (PYXS). This can be considered as Overvalued.


Can you provide the profitability details for PYXIS ONCOLOGY INC?

PYXIS ONCOLOGY INC (PYXS) has a profitability rating of 1 / 10.


What is the financial health of PYXIS ONCOLOGY INC (PYXS) stock?

The financial health rating of PYXIS ONCOLOGY INC (PYXS) is 3 / 10.